CN104013595B - 一种盐酸司来吉兰制剂及其制备工艺 - Google Patents
一种盐酸司来吉兰制剂及其制备工艺 Download PDFInfo
- Publication number
- CN104013595B CN104013595B CN201310065036.3A CN201310065036A CN104013595B CN 104013595 B CN104013595 B CN 104013595B CN 201310065036 A CN201310065036 A CN 201310065036A CN 104013595 B CN104013595 B CN 104013595B
- Authority
- CN
- China
- Prior art keywords
- selegilinehydrochloride
- preparation
- prepared
- capsule
- extrusion spheronization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 229960003678 selegiline hydrochloride Drugs 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000002775 capsule Substances 0.000 claims abstract description 22
- 238000001125 extrusion Methods 0.000 claims abstract description 12
- 238000005563 spheronization Methods 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 13
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000008213 purified water Substances 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000000693 micelle Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 206010030312 On and off phenomenon Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 1
- SKHIBNDAFWIOPB-UHFFFAOYSA-N hydron;2-phenylethanamine;chloride Chemical compound Cl.NCCC1=CC=CC=C1 SKHIBNDAFWIOPB-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940048346 phenethylamine hydrochloride Drugs 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 229940016341 selegiline hydrochloride 5 mg Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
参数 | 常规技术制备 | 本发明制备 |
含量均匀度(A+1.80S值) | 14.1 | 10.6 |
装量差异范围 | ±5.0%其中有一粒超出该范围 | 所测重量都在±3.0%内 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310065036.3A CN104013595B (zh) | 2013-03-01 | 2013-03-01 | 一种盐酸司来吉兰制剂及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310065036.3A CN104013595B (zh) | 2013-03-01 | 2013-03-01 | 一种盐酸司来吉兰制剂及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104013595A CN104013595A (zh) | 2014-09-03 |
CN104013595B true CN104013595B (zh) | 2016-08-24 |
Family
ID=51430782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310065036.3A Active CN104013595B (zh) | 2013-03-01 | 2013-03-01 | 一种盐酸司来吉兰制剂及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104013595B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104622826B (zh) * | 2015-03-02 | 2018-08-10 | 上海普康药业有限公司 | 一种枸橼酸莫沙必利片剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2280604A (en) * | 1993-07-02 | 1995-02-08 | Resource Medical Limited | Tablet formulation of betahistine and selegiline |
US5817336A (en) * | 1993-04-02 | 1998-10-06 | Orion-Yhtyma Oy | Composition containing selegiline |
-
2013
- 2013-03-01 CN CN201310065036.3A patent/CN104013595B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817336A (en) * | 1993-04-02 | 1998-10-06 | Orion-Yhtyma Oy | Composition containing selegiline |
GB2280604A (en) * | 1993-07-02 | 1995-02-08 | Resource Medical Limited | Tablet formulation of betahistine and selegiline |
Also Published As
Publication number | Publication date |
---|---|
CN104013595A (zh) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104736144B (zh) | 外排抑制剂组合物和使用此组合物治疗的方法 | |
CN104703584A (zh) | 可吸入药物组合物 | |
US11007201B2 (en) | Corticotropin releasing factor receptor antagonists | |
JP7285222B2 (ja) | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 | |
JP2012517987A5 (ja) | 吸入用の医薬組成物のfpd特性を設定する方法 | |
JP2014534196A5 (zh) | ||
TW200820992A (en) | Nanoparticulate formulations of modafinil | |
EP0146363B1 (en) | Synergistic pharmaceutical compositions, their production and use | |
TW201726113A (zh) | 易服用性固態製劑用粒子組成物及含有該粒子組成物之易服用性固態製劑 | |
CN104013595B (zh) | 一种盐酸司来吉兰制剂及其制备工艺 | |
CN104510717B (zh) | 奥氮平口崩片及其制备方法 | |
HUE031442T2 (en) | Use of Clidinium to improve sleep quality in respiratory patients | |
Huang et al. | Metoprolol tartrate sustained-release binary matrix microspheres for oral administration produced by novel ultra-fine particle processing system | |
CN104622854A (zh) | 含有盐酸氨溴索和硫酸沙丁胺醇的片剂 | |
CN103251567A (zh) | 一种阿戈美拉汀片剂及其制备方法 | |
CN106214646B (zh) | 一种水飞蓟宾葡甲胺制剂 | |
CN105395512B (zh) | 一种盐酸环苯扎林控释片 | |
JP6055076B2 (ja) | シネフリン及びトピラマートを含む組み合わせ製品 | |
WO2016051424A4 (en) | A formulation useful for delivery of neuro protecting agent | |
CN106692116A (zh) | 一种含异佛司可林的胶囊型吸入粉雾剂 | |
CN105641706A (zh) | 一种米拉贝隆药物组合物及其制备方法 | |
CN105796498A (zh) | 一种粉末包衣叶酸及其制备方法 | |
CN104887635B (zh) | 一种盐酸西替利嗪片及其制备工艺 | |
CN109419780A (zh) | 一种盐酸索他洛尔片剂及其制备方法 | |
JP2006528628A (ja) | ヒーブ(ウマの呼吸器障害、heaves)の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hydrochloric acid selegiline preparation and preparation process thereof Effective date of registration: 20190328 Granted publication date: 20160824 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2019340000162 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200722 Granted publication date: 20160824 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: 2019340000162 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation of selegiline hydrochloride and its preparation technology Effective date of registration: 20201222 Granted publication date: 20160824 Pledgee: China Construction Bank Taihe sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2020340000064 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211227 Granted publication date: 20160824 Pledgee: China Construction Bank Taihe sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2020340000064 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Selegilan hydrochloride preparation and its preparation process Effective date of registration: 20211230 Granted publication date: 20160824 Pledgee: China Construction Bank Taihe sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2021340000043 |